| First Author | An Z | Year | 2018 |
| Journal | Oncogene | Volume | 37 |
| Issue | 12 | Pages | 1561-1575 |
| PubMed ID | 29321659 | Mgi Jnum | J:261026 |
| Mgi Id | MGI:6153394 | Doi | 10.1038/s41388-017-0045-7 |
| Citation | An Z, et al. (2018) Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies. Oncogene 37(12):1561-1575 |
| abstractText | Amplification of epidermal growth factor receptor (EGFR) and its active mutant EGFRvIII occurs frequently in glioblastoma (GBM). While EGFR and EGFRvIII play critical roles in pathogenesis, targeted therapy with EGFR-tyrosine kinase inhibitors (TKIs) or antibodies has only shown limited efficacy in patients. Here we discuss signaling pathways mediated by EGFR/EGFRvIII, current therapeutics, and novel strategies to target EGFR/EGFRvIII-amplified GBM. |
